Company Overview and News

8
5 Industrials 'Safer' Dividend WallStars Gain 50% To 68.4% Per September Broker Estimates

2018-09-10 seekingalpha
WallStars are distinguished by positive broker target-price upsides. 'Safer' dividend industrials WallStar 1yr. target=gains for DAL, CAT, MAN, TTEC, CMRE, GMLP, DLX, CPA, GMLP. CPLP, & ATTO ranged 19.88%-68.45%.
CPLP HMLP CAT MAN SFL WM BGSF ABB CMRE GMLP CAJ ABLZF DLX DAL

3
7 Large Foreign Stocks With Big Upside for US Investors

2018-09-10 247wallst
2018 has been a strange time for investors. While the U.S. stock market sits close to all-time highs, many of the emerging and other developed markets nations have seen their shares take a beating. Wall Street analysts have made numerous calls signaling that there now may be more upside and opportunities in some larger international companies.
BLT BHPBF BP BP.A BP.B ABB BP BHP CCE ABLZF BBL TRI BHP MS BPAQF BHPLF

21
Top Research Reports: UnitedHealth, PepsiCo, Amgen & More

2018-08-14 zacks - 1
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features updated research reports on 12 major stocks, including UnitedHealth (UNH), PepsiCo (PEP) and Amgen (AMGN). These research reports have been hand-picked from roughly 70 reports published by our analyst team today.
FOX GD AMGN CQP LNG CVS CLH ABB 7018 PEP AMT CME ABLZF TXT UNH FOXA

1
ABB Poised on Solid Traction Across Markets, Risks Remain

2018-08-14 zacks
On Aug 14, we issued an updated research report on ABB Ltd (ABB - Free Report) .
ABB AIMC ABLZF AIT

21
General Electric: Is Flannery Throwing In The Towel?

2018-08-14 seekingalpha
New asset sales appear to show a continuation of the multi-year structural rebuilding strategy that has been laid-out by CEO John Flannery.
BHI ABB SBGSY GEC GE CATR CAT ABLZF GNE SBGSF

24
GE Is Preparing $1.5 Billion Sale of Power-Conversion Unit - Bloomberg

2018-08-10 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
SBGSY DSLV GEC GE CATR VIIX DGLD CAT CSSLF VIIZ CS SBGSF BHI CSGKF ABB UGLD ABLZF GNE ZIV USLV TVIX XIV

112
7 High-Risk Dividend Stocks for Adventurous Income Investors

2018-08-08 investorplace - 2
Investing for income usually results in quieter, and lower-risk, investment strategies. The best dividend stocks tend to be more mature and lower-growth, which is why they distribute cash to shareholders rather than reinvesting it in their businesses. The goal of most income investors is to protect principal by buying quality companies who will grow dividends over time, rather than chasing ‘hot’ stocks with higher risk.
IBM HON GE F GEC ETH SCS ABB MAT AMZN FTRPR HON MLHR ABLZF TSLA GNE SPG EMR KNL SSI GMAN MAC FTR

8
27 Industrial Sector 'Safer' Dividend WallStars Tagged For July

2018-07-31 seekingalpha
WallStars are distinguished by positive broker target price-upsides. 'Safer' dividend industrials WallStar 1yr. target-gains for LMT, MSM, KMT, CAT, MLHR, HMLP, DAL, CMRE, GMLP. CPA, & CPLP ranged 16.57%-45.79%.
LMT KMT CPLP HMLP CAT SFL WM CMI ETN ABB CMRE GMLP CAJ ABLZF DAL

16
A Wonderful Company At A Fair Price: Time To Buy?

2018-07-27 seekingalpha
3M Company is a high-quality, blue-chip industrial conglomerate. It is currently trading -21% below its 52-week high.
GEC MTSI GE UTX ABB KMI ABLZF GNE KMR CVB KMRFZ

 
ABB Q2 Earnings Beat Estimates, Orders & Margin Grow Y/Y

2018-07-20 zacks
ABB Ltd. (ABB - Free Report) reported better-than-expected bottom-line results for second-quarter 2018 on the back of strong growth in orders and improvement in the margin. Impressive results seem to have lifted investors’ sentiments for the stock, as evident from 2.7% gain in the share price yesterday. The company’s operational earnings in the reported quarter were 38 cents per share, surpassing the Zacks Consensus Estimate of 36 cents by 5.
ABB AZZ KWHIF CPST ABLZF KWHIY WISEX 7012 ETN IQV

 
ABB LTD. (ABB) CEO Ulrich Spiesshofer on Q2 2018 Results - Earnings Call Transcript

2018-07-19 seekingalpha
Ladies and gentlemen, good morning or good afternoon. Welcome to the ABB Q2 2018 Results Conference Call. I'm Mirona, the Chorus Call operator. [Operator Instructions] The conference must not be recorded for publication or broadcast.
ABB ABLZF MS BEAV

1
ABB LTD. 2018 Q2 - Results - Earnings Call Slides

2018-07-19 seekingalpha - 1
The following slide deck was published by ABB LTD. in conjunction with their 2018 Q2 earnings call.
ABB ABLZF

1
Will Solid End-Market Growth Boost ABB's Earnings in Q2?

2018-07-17 zacks
ABB Ltd (ABB - Free Report) is scheduled to report second-quarter 2018 results on Jul 19.
ABB ABLZF MTW ETN

32
Union leaders to meet General Electric in bid to save Virginia jobs

2018-06-12 reuters
NEW YORK (Reuters) - Union leaders plan to meet with General Electric Co on Wednesday in a bid to avert closure of a Virginia factory that makes controls for GE’s power plants, the company and the union said on Tuesday.
ABB GEC GE ABLZF GNE

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

16h - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

17h - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

19h - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

CUSIP: H0010V101